Simultaneous Administration of a Luteinizing Hormone Releasing Hormone Agonist and Diethylstilbestrol in the Initial Treatment of Prostatic Cancer

Publisher Website
Google Scholar
Abstract
It is well known that the first administration of luteinizing hormone releasing hormone (LH-RH) analogues induces an initial increase of luteinizing hormone (LH) release and a subsequent rise in testosterone (T). This rise is maximal after 3–4 days and is followed by a steady fall of LH and T. Several investigators have reported flare-up symptoms in patients with advanced prostatic cancer, associated with the rise of T, when treated by LH-RH analogue alone. In order to prevent these flare-up symptoms, we treated 20 patients with advanced prostatic cancer with an association of a LH-RH analogue (Zoladex Depot®) and diethylstilbestrol (DES) l mg/day. DES was given for 14 days, starting 1 days before the first Zoladex Depot injection. T fell to near castrate levels within a few days, but rose again 3–4 days after the administration of the LH-RH analogue to pretreatment values before returning to castrate levels. No clinical flare-up manifestations were recorded. We conclude that combination treatment with DES can prevent the flare-up symptoms induced by LH-RH analogue in patients with prostatic cancer.

This publication has 0 references indexed in Scilit: